<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <billNumber>102</billNumber>
    <createDate>2019-01-11T05:40:18Z</createDate>
    <updateDate>2021-06-11T21:58:51Z</updateDate>
    <originChamber>Senate</originChamber>
    <billType>S</billType>
    <introducedDate>2019-01-10</introducedDate>
    <congress>116</congress>
    <recordedVotes />
    <committees>
      <billCommittees>
        <item>
          <systemCode>sshr00</systemCode>
          <name>Health, Education, Labor, and Pensions Committee</name>
          <chamber>Senate</chamber>
          <type>Standing</type>
          <subcommittees />
          <activities>
            <item>
              <name>Referred to</name>
              <date>2019-01-10T20:57:43Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <committeeReports />
    <relatedBills>
      <item>
        <latestTitle>Prescription Drug Price Relief Act of 2019</latestTitle>
        <congress>116</congress>
        <number>465</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-01-25</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2019-01-10</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2019-01-10</actionDate>
        <links />
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees />
      </item>
      <actionTypeCounts>
        <referredToCommittee>1</referredToCommittee>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S000033</bioguideId>
        <fullName>Sen. Sanders, Bernard [I-VT]</fullName>
        <firstName>Bernard</firstName>
        <middleName />
        <lastName>Sanders</lastName>
        <party>I</party>
        <state>VT</state>
        <identifiers>
          <lisID>1010</lisID>
          <bioguideId>S000033</bioguideId>
          <gpoId>8270</gpoId>
        </identifiers>
        <byRequestType />
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001288</bioguideId>
        <fullName>Sen. Booker, Cory A. [D-NJ]</fullName>
        <firstName>Cory</firstName>
        <middleName>A.</middleName>
        <lastName>Booker</lastName>
        <party>D</party>
        <state>NJ</state>
        <identifiers>
          <lisID>2194</lisID>
          <bioguideId>B001288</bioguideId>
          <gpoId />
        </identifiers>
        <sponsorshipDate>2019-01-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <bioguideId>B001277</bioguideId>
        <fullName>Sen. Blumenthal, Richard [D-CT]</fullName>
        <firstName>Richard</firstName>
        <middleName />
        <lastName>Blumenthal</lastName>
        <party>D</party>
        <state>CT</state>
        <identifiers>
          <lisID>2076</lisID>
          <bioguideId>B001277</bioguideId>
          <gpoId>8332</gpoId>
        </identifiers>
        <sponsorshipDate>2019-01-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <bioguideId>G000555</bioguideId>
        <fullName>Sen. Gillibrand, Kirsten E. [D-NY]</fullName>
        <firstName>Kirsten</firstName>
        <middleName>E.</middleName>
        <lastName>Gillibrand</lastName>
        <party>D</party>
        <state>NY</state>
        <identifiers>
          <lisID>1866</lisID>
          <bioguideId>G000555</bioguideId>
          <gpoId>8336</gpoId>
        </identifiers>
        <sponsorshipDate>2019-01-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <bioguideId>H001075</bioguideId>
        <fullName>Sen. Harris, Kamala D. [D-CA]</fullName>
        <firstName>Kamala</firstName>
        <middleName>D.</middleName>
        <lastName>Harris</lastName>
        <party>D</party>
        <state>CA</state>
        <identifiers>
          <lisID>2301</lisID>
          <bioguideId>H001075</bioguideId>
          <gpoId />
        </identifiers>
        <sponsorshipDate>2019-01-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <bioguideId>W000817</bioguideId>
        <fullName>Sen. Warren, Elizabeth [D-MA]</fullName>
        <firstName>Elizabeth</firstName>
        <middleName>A.</middleName>
        <lastName>Warren</lastName>
        <party>D</party>
        <state>MA</state>
        <identifiers>
          <lisID>2182</lisID>
          <bioguideId>W000817</bioguideId>
          <gpoId />
        </identifiers>
        <sponsorshipDate>2019-01-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <bioguideId>K000367</bioguideId>
        <fullName>Sen. Klobuchar, Amy [D-MN]</fullName>
        <firstName>Amy</firstName>
        <middleName />
        <lastName>Klobuchar</lastName>
        <party>D</party>
        <state>MN</state>
        <identifiers>
          <lisID>1826</lisID>
          <bioguideId>K000367</bioguideId>
          <gpoId>8249</gpoId>
        </identifiers>
        <sponsorshipDate>2019-07-23</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <sponsorshipWithdrawnDate />
      </item>
    </cosponsors>
    <cboCostEstimates />
    <laws />
    <notes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Administrative remedies</name>
          </item>
          <item>
            <name>Asia</name>
          </item>
          <item>
            <name>Business records</name>
          </item>
          <item>
            <name>Canada</name>
          </item>
          <item>
            <name>Civil actions and liability</name>
          </item>
          <item>
            <name>Competition and antitrust</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Europe</name>
          </item>
          <item>
            <name>France</name>
          </item>
          <item>
            <name>Germany</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Government studies and investigations</name>
          </item>
          <item>
            <name>Health care costs and insurance</name>
          </item>
          <item>
            <name>Health information and medical records</name>
          </item>
          <item>
            <name>Inflation and prices</name>
          </item>
          <item>
            <name>Intellectual property</name>
          </item>
          <item>
            <name>Japan</name>
          </item>
          <item>
            <name>Licensing and registrations</name>
          </item>
          <item>
            <name>Manufacturing</name>
          </item>
          <item>
            <name>Marketing and advertising</name>
          </item>
          <item>
            <name>Medical research</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
          <item>
            <name>Research and development</name>
          </item>
          <item>
            <name>United Kingdom</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <actionDate>2019-01-10</actionDate>
          <actionDesc>Introduced in Senate</actionDesc>
          <lastSummaryUpdateDate>2019-02-05T14:37:16Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Prescription Drug Price Relief Act of 2019</b></p> <p>This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.</p> <p>Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.</p> <p>The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures. </p>]]></text>
          <updateDate>2019-01-10T05:00:00Z</updateDate>
          <name>Introduced in Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <title>Prescription Drug Price Relief Act of 2019</title>
    <titles>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <parentTitleType>Short Title</parentTitleType>
        <title>Prescription Drug Price Relief Act of 2019</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <title>A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <parentTitleType />
        <title>Prescription Drug Price Relief Act of 2019</title>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <amendments />
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2019-01-10T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116s102is/xml/BILLS-116s102is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2019-01-10</actionDate>
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <links />
    </latestAction>
    <calendarNumbers />
    <version>1.0.0</version>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

